医药行业周报：甲磺酸沙非胺片在华获批，用于治疗帕金森

Industry Investment Rating - The report maintains a positive outlook on the pharmaceutical industry [1] Core Views - The pharmaceutical sector outperformed the CSI 300 index by 0 77 percentage points on December 2 2024 with a sector increase of 1 56% [1] - The hospital sub-sector led with a 2 34% increase followed by medical equipment at 2 13% and in-vitro diagnostics at 2 00% [1] - The blood products sub-sector lagged with a 0 53% increase [1] - Top performing stocks included Kangzhi Pharmaceutical (+20 07%) Frontier Biotech (+20 00%) and Mengke Pharmaceutical (+10 55%) [1] - The NMPA approved Zambon's new drug Safinamide Mesylate Tablets for Parkinson's disease treatment in China [1] Sub-sector Ratings - Other pharmaceutical and medical sectors are rated as neutral [1] - Chemical pharmaceuticals and traditional Chinese medicine production have no rating [1] - Biological pharmaceuticals are rated as neutral [1] Company News - Hengrui Pharmaceuticals repurchased 4 9361 million shares (0 08% of total shares) at a price range of 39 00-57 01 yuan per share totaling 207 million yuan [1] - Nuosige repurchased 1 442 million shares (1 49% of total shares) at a price range of 35 06-43 15 yuan per share totaling 56 million yuan [1] - Zhaoyan New Drug repurchased 2 1031 million shares (0 28% of total shares) at a price range of 13 20-18 15 yuan per share totaling 33 million yuan [1] - Asymchem repurchased 1 2301 million shares (3 62% of total shares) at a price range of 71 65-102 00 yuan per share totaling 1 billion yuan [1]